| 1 |
NCT00806845 |
Completed |
Examination of B Cell Responses in Human Blood |
|
|
Observational |
|
- Regenerative Medicine Network
- University of Leipzig
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Antigen specific B-cell responses
|
50 |
All |
18 Years to 65 Years (Adult) |
NCT00806845 |
RegMedNet-001 |
|
July 2008 |
December 2009 |
February 2010 |
December 11, 2008 |
May 13, 2015 |
|
- Universität Leipzig
Leipzig, Sachsen, Germany
|
| 2 |
NCT00801697 |
Completed |
Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector |
|
- Biological: DNA Vaccine
- Biological: DNA Vaccine placebo
- Biological: rAd35
- (and 3 more...)
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- HIV Vaccine Trials Network
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- Local and systemic reactogenicity signs and symptoms, laboratory measures of safety, and adverse and expedited adverse events
- Magnitude and frequency of immune responses between HIV-1 clade A env rAD35 and rAd5 vaccines when given as a boost after DNA vaccine
- Magnitude and frequency of immune responses between clade A env rAD35 vaccine primed by Ad35 versus DNA
- (and 2 more...)
|
192 |
All |
18 Years to 50 Years (Adult) |
NCT00801697 |
HVTN 077
10702 |
|
February 2009 |
February 2011 |
April 2015 |
December 3, 2008 |
June 21, 2016 |
|
- Alabama CRS
Birmingham, Alabama, United States - Bridge HIV CRS
San Francisco, California, United States - The Hope Clinic of the Emory Vaccine Center CRS
Decatur, Georgia, United States - (and 7 more...)
|
| 3 |
NCT00808002 |
Completed |
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine |
|
- Drug: Raltegravir
- Drug: Maraviroc
- Drug: Tenofovir/Emtricitabine
|
Interventional |
Phase 3 |
- Germans Trias i Pujol Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change at 48 weeks in the slope of decay of integrated and unintegrated viral DNA in PBMCs.
- Decay of residual HIV-1 replication under maraviroc intensification assessed by an ultrasensitive RT-PCR assay with a lower limit of quantification of 5 copies/mL.
- Blips during the study (viral load >50 copies/mL, preceded and followed by determinations <50 copies/mL in previous and posterior controls).
- (and 8 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT00808002 |
MARAVIBOOST |
|
February 2009 |
November 2011 |
November 2011 |
December 15, 2008 |
September 8, 2014 |
|
- Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain - Hospital Clinic i Provincial de Barcelona
Barcelona, Spain
|
| 4 |
NCT00807443 |
Completed |
Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1 |
|
|
Interventional |
Phase 2 |
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- To evaluate, by means of a clinical trial, the effect of therapy with an integrase inhibitor (Raltegravir) on the cell reservoir of HIV-1 on patients taking HAART
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT00807443 |
ERRADVIH-02 |
|
September 2009 |
December 2011 |
December 2011 |
December 12, 2008 |
February 1, 2013 |
|
- Hospital Universitario Ramon Y Cajal
Madrid, Spain
|
| 5 |
NCT00796263 |
Recruiting |
Antiretroviral Therapy for Acute HIV Infection |
|
- Drug: HAART
- Drug: Mega-HAART
|
Interventional |
Phase 3 |
- South East Asia Research Collaboration with Hawaii
- Thai Red Cross AIDS Research Centre
- Pfizer
- (and 3 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HIV-1 plasma viral RNA measurements and CD4 counts during follow-up and after therapy
- Number of HIV and non-HIV related clinical events
- Adverse events related to HAART
- (and 2 more...)
|
536 |
All |
18 Years and older (Adult, Senior) |
NCT00796263 |
HAART for Acute HIV infection |
AAHIV |
April 2009 |
April 2021 |
July 2021 |
November 24, 2008 |
April 19, 2018 |
|
- Thai Red Cross AIDS Research Centre
Bangkok, Thailand
|
| 6 |
NCT00795483 |
Completed |
Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients' Cohort |
|
- Drug: Zoledronic acid
- Behavioral: Lifestyle modifications
|
Interventional |
Phase 4 |
- Germans Trias i Pujol Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Increase in lumbar (L2-4) and femoral (trochanter, femur neck, total femur and hip) t-score bone mineral density
- Adverse events
- Lab tests
- (and 2 more...)
|
33 |
All |
18 Years and older (Adult, Senior) |
NCT00795483 |
VIH-ZOL |
|
November 2009 |
November 2011 |
November 2011 |
November 21, 2008 |
August 9, 2012 |
|
- Germans Trias i Pujol Hospital
Badalona, Barcelona, Spain
|
| 7 |
NCT00803543 |
Completed
Has Results |
Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding |
|
- Drug: Valacyclovir
- Drug: Placebo
|
Interventional |
Not Applicable |
- University of Alabama at Birmingham
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Herpes Simplex Virus Type 2 Recurrence
- CD4 Count
- Number of Participants With an HIV Viral Load of <500 Copies/ml
- Rate of Asymptomatic HSV-2 Genital Shedding
|
103 |
All |
19 Years and older (Adult, Senior) |
NCT00803543 |
F080718009 |
|
January 2009 |
April 2014 |
April 2014 |
December 5, 2008 |
July 13, 2017 |
July 13, 2017 |
- Community Care Building
Birmingham, Alabama, United States
|
| 8 |
NCT00799058 |
Completed |
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States |
|
- Drug: dapivirine 4789
- Drug: dapivirine gel 4759
- Drug: Drug placebo
|
Interventional |
Phase 3 |
- International Partnership for Microbicides, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- The proportion of women who have abnormal observations at each visit during the pelvic/speculum examination and colposcopy, and the proportion of women who report at least one adverse event.
- Changes in the vaginal flora and vaginal pH
- The distribution of dapivirine levels observed in plasma, vaginal fluid and vaginal tissue samples at each specified time point
|
180 |
Female |
18 Years to 40 Years (Adult) |
NCT00799058 |
IPM 020 |
|
June 2009 |
June 2015 |
November 2015 |
November 27, 2008 |
September 15, 2017 |
|
- University of Alabama at Birmingham, Alabama Microbicide Clinical Research Site (AMCRS)
Birmingham, Alabama, United States - Harbor-UCLA Medical Center
Torrance, California, United States - University of Illinois at Chicago
Chicago, Illinois, United States - (and 2 more...)
|
| 9 |
NCT00798772 |
Completed |
Micronutrients and Antioxidants in HIV Infection |
|
- Dietary Supplement: Micronutrients and antioxidants
- Dietary Supplement: Multivitamins and minerals
|
Interventional |
Not Applicable |
- Ottawa Hospital Research Institute
- CIHR Canadian HIV Trials Network
- Ontario HIV Treatment Network
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time from baseline to CD4+ cell count <350 cells/mm3 (confirmed by two measures at least one week apart), or emergence of documented CDC-defined AIDS-defining illness, or start of ART
- Non-AIDS related adverse events
- Tolerance of and adherence to study medication
- (and 8 more...)
|
171 |
All |
18 Years and older (Adult, Senior) |
NCT00798772 |
CTN 238 |
MAINTAIN |
January 2009 |
May 2014 |
December 6, 2017 |
November 26, 2008 |
April 17, 2018 |
|
- The Ottawa Hospital, General Campus
Ottawa, Ontario, Canada
|
| 10 |
NCT00807625 |
Completed |
Impact of Different Contraceptives on the Immune System of HIV Infected Women in Zambia |
- HIV
- Contraception
- HIV Infections
|
- Drug: Depo Provera
- Device: Copper T Intrauterine contraception device
|
Interventional |
Phase 2 |
- University of Alabama at Birmingham
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- T-cell activation
- CD4+ cell decline
- Cervical viral load
|
66 |
Female |
16 Years and older (Child, Adult, Senior) |
NCT00807625 |
F071227004 |
MSRC |
November 2008 |
July 2010 |
July 2010 |
December 12, 2008 |
July 13, 2012 |
|
- The Centre for Infectious Disease Research in Zambia
Lusaka, Zambia
|
| 11 |
NCT00797381 |
Unknown † |
Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia |
- HIV Infection
- Hemophilia A
|
|
Observational |
|
- Shanghai Public Health Clinical Center
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- The safety and tolerability of MK-0518 400 mg b.i.d. compared to placebo, both in combination with OBT, assessed by review of the accumulated safety data in HIV-infected patients with hemophilia.
- Antiretroviral activity of MK-0518 400 mg b.i.d. compared to placebo, both in combination with OBT.
|
100 |
All |
18 Years to 65 Years (Adult) |
NCT00797381 |
CN2009 |
|
May 2009 |
October 2010 |
May 2011 |
November 25, 2008 |
November 25, 2008 |
|
- Shanghai Public Health Clinical Center
Shanghai, Jinshan, China
|
| 12 |
NCT00796146 |
Recruiting |
Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population |
|
|
Observational |
|
- South East Asia Research Collaboration with Hawaii
- Armed Forces Research Institute of Medical Sciences, Thailand
- Thai Red Cross AIDS Research Centre
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of HIV and non-HIV related clinical events
- demographics and behavioral risk factors for those identified with acute HIV infection
- neurocognitive function and neuroimaging findings in acute HIV infection as well as describe immune response, HIV-1 genotypes and sequences in the cerebrospinal fluid
- (and 4 more...)
|
536 |
All |
18 Years and older (Adult, Senior) |
NCT00796146 |
SEARCH010/ RV 254 |
|
April 2009 |
April 2019 |
July 2019 |
November 24, 2008 |
April 18, 2018 |
|
- Thai Red Cross AIDS Research Centre
Bangkok, Thailand
|
| 13 |
NCT00801515 |
No longer available |
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029 |
|
|
Expanded Access |
|
|
Industry |
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00801515 |
A4001090 |
|
August 2009 |
July 2011 |
July 2011 |
December 3, 2008 |
July 25, 2011 |
|
- Pfizer Investigational Site
Montreal, Quebec, Canada
|
| 14 |
NCT00791700 |
Active, not recruiting
Has Results |
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children |
- Human Immunodeficiency Virus
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetic (PK) Parameters for Participants With Data in Stage 1 Enrolled in Stage 2 - Week 48
- PK Parameters for Stage 1 Participants Enrolled in Stage 2 - Week 2 Results for Stage 2 Doses - AUCtau (Area Under the Curve at Steady State)
- PK Parameters for Stage 1 Participants Enrolled in Stage 2 - Week 2 Results for Stage 2 Doses - Tmax (Time at Maximum Concentration)
- (and 16 more...)
|
103 |
All |
2 Years to 18 Years (Child, Adult) |
NCT00791700 |
A4001031
2008-006873-33 |
|
April 22, 2009 |
April 14, 2015 |
November 29, 2018 |
November 14, 2008 |
March 14, 2018 |
February 25, 2016 |
- Children's Hospital Los Angeles
Los Angeles, California, United States - Children's Hospital of Orange County
Orange, California, United States - Alfred I. DuPont Hospital for Children
Wilmington, Delaware, United States - (and 39 more...)
|
| 15 |
NCT00802802 |
Completed |
Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children |
- HIV Infections
- Tuberculosis
|
- Drug: Efavirenz (EFV)
- Drug: Rifampin-containing anti-TB therapy
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Any treatment-related Grade 2B rash or Grade 3 or 4 toxicity requiring permanent discontinuation of efavirenz (EFV)
- Death
- A safety event as defined as a Grade 4 life-threatening toxicity or Grade 4 toxicity accompanying a serious adverse event (SAE) (e.g., hospitalization) or death that is judged to be at least possibly related to EFV
- (and 2 more...)
|
155 |
All |
3 Months to 35 Months (Child) |
NCT00802802 |
P1070
10633
IMPAACT P1070 |
|
October 2009 |
March 2016 |
March 2016 |
December 5, 2008 |
May 10, 2016 |
|
- Byramjee Jeejeebhoy Medical College (BJMC) CRS
Pune, Maharashtra, India - Soweto IMPAACT CRS
Johannesburg, Gauteng, South Africa - Shandukani Research CRS
Johannesburg, Gauteng, South Africa - (and 4 more...)
|
| 16 |
NCT00795210 |
Completed
Has Results |
Effects of Short-term Growth Hormone in HIV-infected Patients |
|
- Drug: Growth hormone
- Drug: Growth Hormone Releasing Hormone
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug
- Insulin Sensitivity
|
25 |
All |
18 Years to 60 Years (Adult) |
NCT00795210 |
DK63639A
R01DK063639 |
|
February 2009 |
November 2012 |
November 2012 |
November 21, 2008 |
January 8, 2014 |
January 8, 2014 |
- MGH
Boston, Massachusetts, United States
|
| 17 |
NCT00795717 |
Completed
Has Results |
Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial |
- Cardiovascular Disease
- HIV Infection
|
- Drug: Lovaza
- Drug: Placebo
|
Interventional |
Phase 4 |
- Todd Conley
- Tufts University
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Baseline Mean Serum Triglyceride Level at Study End
- Serum HDL Level
- Brachial Artery Reactivity
|
41 |
All |
18 Years to 65 Years (Adult) |
NCT00795717 |
LVZ111888
011293-GSK Contract Reference# |
HALO |
July 2008 |
October 2010 |
October 2010 |
November 21, 2008 |
December 8, 2014 |
December 8, 2014 |
- Tufts University School of Medicine
Boston, Massachusetts, United States
|
| 18 |
NCT00801879 |
Completed |
Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection |
- Staphylococcus Aureus
- HIV Infections
|
- Drug: Mupirocin calcium ointment, 2%
- Drug: Placebo ointment
|
Interventional |
Phase 4 |
- Columbia University
- GlaxoSmithKline
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / Industry / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Nasal colonization with Staphylococcus aureus
- Infection with Staphylococcus aureus
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT00801879 |
AAAB0129
K08AI072043 |
|
September 2003 |
April 2006 |
April 2006 |
December 4, 2008 |
October 29, 2014 |
|
- Project Samaritan Inc.
Bronx, New York, United States - Columbia University
New York, New York, United States
|
| 19 |
NCT00796770 |
Completed |
Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial) |
|
- Biological: Dendritic Cell Vaccine
|
Interventional |
Phase 1 |
- Baylor Research Institute
- French National Agency for Research on AIDS and Viral Hepatitis
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the safety of the vaccination schedule at week 24 and the safety of the Analytical Treatment Interruption at week 48 in HIV-1 infected patients.
- To evaluate immune responses using several defined assays as well as viral and CD4+ T cell status
|
19 |
All |
18 Years and older (Adult, Senior) |
NCT00796770 |
008-017 |
|
November 2008 |
September 2011 |
September 2011 |
November 24, 2008 |
June 12, 2017 |
|
- Baylor University Medical Center
Dallas, Texas, United States
|
| 20 |
NCT00797030 |
Unknown † |
Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus |
- Dry Eye Syndromes
- HIV Seropositivity
|
- Drug: cyclosporine and sodium carboximethycellulose
- Drug: sodium carboximethycellulose
|
Interventional |
Phase 4 |
- Universidade Federal do Rio de Janeiro
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dry eye diagnosis was based on a dry eye questionnaire (OSDI), Shirmer I Test, BUT and 1% rose bengal staining of the ocular surface. The same tests were performed at the end of the treatment to verify the improvement of the subjects.
|
20 |
All |
18 Years to 45 Years (Adult) |
NCT00797030 |
dry eye |
|
October 2006 |
July 2008 |
November 2008 |
November 24, 2008 |
November 24, 2008 |
|
- Universidade Federal do Rio de Janeiro
Rio de Janeiro, Brazil
|
| 21 |
NCT00792324 |
Completed |
Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125 |
|
- Drug: Etravirine
- Drug: Efavirenz
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- The rate of neuropsychiatric and central nervous system (CNS) toxicity as measured by the proportion of patients experiencing grade 2-4 neuropsychiatric and CNS toxicity after 12 weeks (as defined by the ACTG adverse event scale).
- The rate of neuropsychiatric and central nervous system (CNS) toxicity after 12 and 24 weeks as measured by the change from baseline by the Hospital Anxiety and Depression Scale (HADS).
- Proportion of patients with viral load below 50 copies/mL at weeks 12 and 24
- (and 6 more...)
|
24 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00792324 |
SSAT 029 |
|
June 2008 |
August 2009 |
August 2009 |
November 17, 2008 |
November 18, 2009 |
|
- Chelsea and Westminster Hospital
London, United Kingdom
|
| 22 |
NCT00799136 |
Completed |
A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL |
- Lymphoma, AIDS Related
- HIV Infections
|
|
Interventional |
Phase 2 |
- Ontario Clinical Oncology Group (OCOG)
- Hoffmann-La Roche
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary outcome for this feasibility study will be medication adherence. Acceptable adherence, defined as compliance to ≥90% of all prescribed doses of cART during the course of chemotherapy, will be measured by pill counting and patient self-report
- Toxicity Lymphoma response Rate Progression -free Survival and Overall Survival Pharmacokinetics
|
6 |
All |
18 Years and older (Adult, Senior) |
NCT00799136 |
OCOG-2007-CATCH
CIHR FRN 79390 |
CATCH |
February 2008 |
December 2012 |
September 2013 |
November 27, 2008 |
September 12, 2013 |
|
- Odette Cancer Centre
Toronto, Ontario, Canada - St. Michael's Hospital
Toronto, Ontario, Canada
|
| 23 |
NCT00799864 |
Recruiting |
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years |
- Human Immuno Deficiency (HIV) Infection
|
- Drug: Rilpivirine
- Drug: Zidovudine
- Drug: Abacavir
- (and 3 more...)
|
Interventional |
Phase 2 |
- Janssen Sciences Ireland UC
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetics of Rilpivirine (TMC278) as measured by maximum plasma concentration (Cmax)
- Pharmacokinetics of Rilpivirine as measured by area under the plasma concentration curve (AUC24)
- Pharmacokinetics of Rilpivirine as measured by time to reach the maximum plasma concentration (tmax)
- (and 7 more...)
|
61 |
All |
6 Years to 17 Years (Child) |
NCT00799864 |
CR002677
TMC278-TiDP38-C213
2008-001696-30 |
|
January 7, 2011 |
January 10, 2020 |
September 28, 2027 |
December 1, 2008 |
March 29, 2018 |
|
- SUNY Upstate Medical University
Syracuse, New York, United States - St Jude Children's Research Hospital
Memphis, Tennessee, United States - Children'S Hospital of the King'S Daughters
Norfolk, Virginia, United States - (and 23 more...)
|
| 24 |
NCT00792519 |
Completed |
Cognitive Behavioral Treatment to Reduce Alcohol Use Among HIV-Infected Kenyans |
- Binge Drinking
- Alcohol Abuse
- Alcohol Dependence
- HIV Infections
|
- Behavioral: HIV support group
- Behavioral: CBT
|
Interventional |
Phase 1 |
- Brown University
- Moi Univeristy
- Indiana University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- quantity and frequency of alcohol use
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT00792519 |
0703002442
R21AA016884 |
KHBS |
February 2009 |
December 2009 |
December 2010 |
November 18, 2008 |
June 22, 2011 |
|
- AMPATH Centre
Eldoret, Rift Valley, Kenya
|
| 25 |
NCT00790959 |
Unknown † |
The SASA! Study: An Evaluation of a Community Intervention to Address Gender-based Violence and Reduce HIV/AIDS Risk in Uganda |
- Intimate Partner Violence
- HIV
|
- Behavioral: SASA!
- Other: Control
|
Interventional |
Not Applicable |
- London School of Hygiene and Tropical Medicine
- Raising Voices
- Centre for Domestic Violence Prevention, Uganda
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Past year experience of physical violence by an intimate partner (among women partnered in past year)
- Past year experience of sexual violence by an intimate partner (among women partnered in the past year)
- Acceptability of violence against women
- (and 3 more...)
|
800 |
All |
18 Years to 49 Years (Adult) |
NCT00790959 |
PHHPSASA1 |
SASA! |
October 2007 |
May 2012 |
May 2012 |
November 14, 2008 |
February 22, 2012 |
|
- Raising Voices
Kampala, Uganda
|
| 26 |
NCT00790881 |
Completed |
Artemether/Lumefantrine and Nevirapine Interaction Study in HIV-infected Adults |
|
- Drug: Artemether/Lumefantrine
- Drug: Artemether/ lumefantrine
|
Interventional |
Phase 4 |
- University of Cape Town
- London School of Hygiene and Tropical Medicine
|
Other |
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Lumefantrine plasma concentration
- Point estimates and 90% confidence intervals for the mean ratios of the lumefantrine, artemether and DHA log-transformed Cmax, AUC0-t, AUC0 ∞ , t½,z, tmax and MRT with/without NVP
|
36 |
All |
18 Years and older (Adult, Senior) |
NCT00790881 |
SEACAT 2.4.1
DOH-27-0807-2012 |
|
October 2008 |
August 2009 |
December 2009 |
November 14, 2008 |
June 28, 2010 |
|
- Groote Schuur Hospital, Research ward
Cape Town, South Africa
|
| 27 |
NCT00794391 |
Completed |
Effects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs) |
|
- Behavioral: Motivational interviewing
- Behavioral: Educational intervention
|
Interventional |
Not Applicable |
- Université de Sherbrooke
- Fonds de la Recherche en Santé du Québec
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Risky injecting practices
- Stages of change for risky injecting practices (adapted from Prochaska & DiClemente)
- Drug use (including injecting frequency)
|
219 |
All |
16 Years and older (Child, Adult, Senior) |
NCT00794391 |
13940 (FRSQ ID) |
|
November 2008 |
August 2011 |
August 2011 |
November 20, 2008 |
April 4, 2014 |
|
- Université de Sherbrooke, service de toxicomanie (Campus Longueuil)
Montreal, Quebec, Canada
|
| 28 |
NCT00805272 |
Completed |
Medical and Economical Impact of IGRAs Diagnosis of Latent Tuberculosis in HIV-infected Patients |
- HIV
- Tuberculosis
- Latent Tuberculosis Infection
|
- Other: QTF-TB Gold and T-SPOT TB
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- To evaluate the theoretical therapeutic impact (in terms of CHIMIOPROPHYLAXIE antituberculous theoretically managed) of the tracking of tuberculosis-latent by QTF-TB Gold IT® or T-SPOT.TB among patients HIV.
|
536 |
All |
18 Years and older (Adult, Senior) |
NCT00805272 |
P070311 |
IGRAVIH |
February 2009 |
September 2011 |
February 2012 |
December 9, 2008 |
March 19, 2012 |
|
- Service de médecine interne hôpital saint louis
Paris, France
|
| 29 |
NCT00798265 |
Completed |
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults |
- Human Immunodeficiency Virus
- Human Papillomavirus- 6, 11, 16, 18
- Adolescent
- Papillomavirus Vaccines
|
- Biological: Gardisil
- Behavioral: Survey
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Fold increase in HPV titer following vaccination
- Equivalance of HIV-1 RNA levels in HIV+ patients on HAART vs not on HAART
|
26 |
All |
12 Years to 26 Years (Child, Adult) |
NCT00798265 |
090024
09-C-0024 |
|
November 6, 2008 |
September 22, 2012 |
February 4, 2013 |
November 26, 2008 |
April 20, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 30 |
NCT00796822 |
Completed
Has Results |
Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications |
- HIV
- Cardiovascular Diseases
- Atherosclerosis
|
- Drug: Pentoxifylline
- Drug: Placebo
|
Interventional |
Phase 2 |
- Indiana University
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Flow-mediated Dilation of the Brachial Artery
- Change in Soluble TNF-Receptor I Levels
|
26 |
All |
18 Years and older (Adult, Senior) |
NCT00796822 |
614
R01HL095149 |
|
January 2009 |
October 2011 |
October 2011 |
November 24, 2008 |
November 28, 2017 |
May 17, 2013 |
- Indiana Clinical Research Center
Indianapolis, Indiana, United States
|
| 31 |
NCT00797654 |
Completed |
HIV Prevention and Trauma Treatment in Men Who Have Sex With Men and Who Have a History of Sexual Abuse |
|
- Behavioral: Information-motivation-behavior skills and cognitive processing therapy
- Behavioral: Pre and Post HIV-Test Counseling
|
Interventional |
Not Applicable |
- Fenway Community Health
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Self-reported sexual risk taking
- Reductions in negative effects of trauma, with cognitive and behavioral variables tested as potential mediators of treatment outcome
|
46 |
Male |
18 Years and older (Adult, Senior) |
NCT00797654 |
R34MH081760-02 |
|
August 2008 |
September 2010 |
May 2011 |
November 25, 2008 |
August 9, 2016 |
|
- Fenway Community Health
Boston, Massachusetts, United States - Fenway Health
Boston, Massachusetts, United States
|
| 32 |
NCT00798538 |
Completed |
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) |
- Buprenorphine
- HIV
- Drug Abuse
- (and 7 more...)
|
- Other: Services will be provided at one site
- Other: Services remain dispersed; i.e., not centralized to one-location or provider.
|
Interventional |
Phase 4 |
- Yale University
- Waterbury Hospital
- Health Resources and Services Administration (HRSA)
- The New York Academy of Medicine
|
Other / U.S. Fed |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Substance use outcomes measured by self-report
- Urine toxicology results
- Retention in and adherence to HIV care
- (and 2 more...)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT00798538 |
H97HA03800-03 |
BELIEVE |
August 2005 |
August 2010 |
August 2010 |
November 26, 2008 |
July 24, 2015 |
|
- Yale AIDS Program
New Haven, Connecticut, United States
|
| 33 |
NCT00792584 |
Completed |
Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz |
|
- Drug: etravirine
- Drug: efavirenz
|
Interventional |
Not Applicable |
- University Hospital, Geneva
- University of Bern
- University of Lausanne Hospitals
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Symptoms and neurological side effects of study drugs
- Levels of daytime sleepiness
- Sleep Quality
- (and 2 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT00792584 |
08-136 |
SWITCH-EE |
November 2008 |
November 2008 |
June 2009 |
November 18, 2008 |
September 12, 2011 |
|
- Geneva Hospital
Geneva, Switzerland
|
Create an RSS feed from your search for:
Download the search results for: